Taken together, our results suggest that the topical application of Hsp90 inhibitors offers greater therapeutic benefits due to a reduced risk of systemic side effects and therefore may be useful for controlling AD and possibly other related inflammatory skin diseases. This evidence concerns the gene HSP90AB1 and inflammatory skin disease.